Incredible progress in HIV treatment

The recent UN summit had good news for all. Progress in HIV treatment is evolving rapidly, moving beyond daily pills toward two major goals: simplifying lifelong therapy and pursuing long-term remission without daily medication. The path to a "functional cure" is becoming clearer. This is good for all infections, not just for those grappling with HIV.

Let us see what it means
From Daily Pills to Long-Acting Therapies
The most immediate progress is in reducing the burden of treatment. New options are making it easier to stay on top of HIV medication.
Less is More with Oral Meds: Newer studies show that two-drug regimens can be as effective as the standard three-drug combinations. A major head-to-head study found that the two-drug pill Dovato was non-inferior to the three-drug pill Biktarvy for people starting treatment, even those with high viral loads. This means fewer medications and potentially fewer side effects over a lifetime.
Monthly or Bi-Monthly Injections: Long-acting injectable therapies are a game-changer for adherence. Regimens combining cabotegravir and rilpivirine, given as a shot every one or two months, effectively maintain viral suppression and can even help reduce chronic immune system activation compared to daily pills.
The Future: Twice-a-Year Shots: Researchers are pushing for even longer intervals. New drugs like lenacapavir and an investigational drug called VH184 are showing the potential to be dosed just twice a year, which could dramatically change the treatment experience for many.

The Push for a "Functional Cure"
The ultimate goal is to allow people to stop daily ART without the virus rebounding. Several innovative strategies are showing promise in clinical trials.
Immunotherapy and "Post-Intervention Control": This is a huge area of focus. Newer strategies aim to train the immune system to control the virus on its own after stopping ART, a state known as "post-intervention control".
Engineered Antibodies: Broadly neutralizing antibodies (bNAbs) are being engineered to last months in the body. In one trial, a combination of bNAbs helped a small group of participants (about 18%) maintain viral suppression for over two years after stopping ART. These antibodies not only block the virus but also seem to "wake up" the immune system, creating a lasting effect similar to a vaccine.
Gene-Modified Cell Therapy: In a proof-of-concept study, a patient's own immune cells were engineered to both attack HIV-infected cells and block the virus from entering new ones. After a single infusion, one person maintained an undetectable viral load for 92 weeks without ART. This approach currently only seems to work in people treated very early after infection.

CRISPR Gene Editing: For the first time, an advanced gene-editing tool (CRISPR-Cas9) packaged in a targeted "nanoblade" was able to successfully cut HIV DNA out of infected cells in animal models, significantly reducing the virus. This is still early-stage research, but it demonstrates a path toward eliminating the virus directly from the body.

The "Cure" Frontier: A Rare but Important Roadmap
The only people who have been completely cured of HIV are a handful of individuals who received stem cell transplants from donors with a rare genetic mutation (CCR5Δ32) that makes them resistant to HIV. The most recent case, reported in 2026, involved a transplant from a sibling with this mutation, leading to full HIV remission.

While this is not a practical treatment for the millions living with HIV due to its extreme risk and cost, it serves as critical "proof-of-concept" that a complete cure is biologically possible and guides further research.

Essentially,  the standard of care is becoming simpler and easier to take. At the same time, research is providing the first solid evidence that a functional cure — a state of long-term remission without daily medication — could become a reality for a broader group of people in the future.
We wish all a healthy life with this progress.

By Jamuna Rangachari